Literature DB >> 21034909

EUS-guided tattooing before laparoscopic distal pancreatic resection (with video).

Anne Marie Lennon1, Naeem Newman, Martin A Makary, Barish H Edil, Eun Ji Shin, Mouen A Khashab, Ralph H Hruban, Christopher L Wolfgang, Richard D Schulick, Samuel Giday, Marcia I Canto.   

Abstract

BACKGROUND: Precise localization of small pancreatic tumors during laparoscopic distal pancreatectomy (LDP) can be difficult because of decreased tactile ability of laparoscopy and the homogeneous appearance of the pancreas and surrounding retroperitoneal fat. Precise localization of the lesion is critical to achieving adequate margins of resection and preserving healthy pancreatic tissue. EUS-guided fine-needle tattooing (EUS-FNT) of a pancreatic lesion before LDP has been described in single case reports, but no large series have reported its effectiveness in patients undergoing LDP.
OBJECTIVE: To assess the feasibility, safety, and efficacy of EUS-FNT in consecutive patients undergoing LDP.
DESIGN: Retrospective cohort study.
SETTING: Tertiary-care referral hospital. PATIENTS: This study involved 30 consecutive patients who underwent LDP from 2008 to 2010. Thirteen had EUS-FNT followed by LDP, and 17 had LDP alone.
INTERVENTIONS: LDP or EUS-FNT with a sterile carbon-particle tattoo followed by LDP. MAIN OUTCOME MEASUREMENTS: The following features were examined: the technical success and complication rates of EUS-FNT, visibility of the tattoo at the time of laparoscopy, durability of the tattoo, and pathologic absence of tumor at the resection margin.
RESULTS: The final pathology of pancreatic lesions of patients who had EUS-FNT was similar to those who had LDP alone. The median resected tumor size was significantly larger for the LDP-alone patients (median 4.0 cm vs 1.3 cm; P = .03). Thirty-one percent (4/13) of lesions in the EUS-FNT group were not visualized by prior preoperative pancreatic protocol CT. EUS-FNT was feasible in all 13 patients at laparoscopy, with R0 resection and negative final pathology margins in all cases. The tattoo was visible in all 13 EUS-FNT cases, with mean time from EUS-FNT to surgery of 20.3 days (range, 3-69 days). There were no significant complications associated with EUS-FNT. LIMITATIONS: Small, retrospective, single-center study.
CONCLUSIONS: Preoperative EUS-FNT of lesions was technically feasible and safe, and it assisted in the localization of lesions in patients before LDP. The carbon particle tattoo was durable and visible in all cases.
Copyright © 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21034909     DOI: 10.1016/j.gie.2010.07.023

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  12 in total

1.  Pancreatic Neuroendocrine Tumors: an Update.

Authors:  Alessandro Paniccia; Barish H Edil; Richard D Schulick
Journal:  Indian J Surg       Date:  2015-10-13       Impact factor: 0.656

2.  GRUPUGE Perspective: Endoscopic Ultrasound-Guided Fine-Needle Tattooing and Fiducial Placement in Pancreatic Cancer.

Authors:  Susana Marques; Miguel Bispo; Sílvia Leite; Teresa Moreira; Ana Caldeira; Pedro Moutinho-Ribeiro; Nuno Nunes
Journal:  GE Port J Gastroenterol       Date:  2020-07-28

3.  Role of preoperative endoscopic ultrasound-guided fine-needle tattooing of a pancreatic head insulinoma.

Authors:  Pornchai Leelasinjaroen; Wuttiporn Manatsathit; Richard Berri; Mohammed Barawi; Frank G Gress
Journal:  World J Gastrointest Endosc       Date:  2014-10-16

Review 4.  Update on pancreatic neuroendocrine tumors.

Authors:  Logan R McKenna; Barish H Edil
Journal:  Gland Surg       Date:  2014-11

5.  Endoscopic ultrasound (EUS)-guided fiducial placement allows localization of small neuroendocrine tumors during parenchymal-sparing pancreatic surgery.

Authors:  Joanna K Law; Vikesh K Singh; Mouen A Khashab; Ralph H Hruban; Marcia Irene Canto; Eun Ji Shin; Payal Saxena; Matthew J Weiss; Timothy M Pawlik; Christopher L Wolfgang; Anne Marie Lennon
Journal:  Surg Endosc       Date:  2013-04-30       Impact factor: 4.584

Review 6.  Endoscopic ultrasound-guided therapies in pancreatic neoplasms.

Authors:  Dennis Yang; Christopher J DiMaio
Journal:  Biomed Res Int       Date:  2015-01-31       Impact factor: 3.411

Review 7.  Diagnosis of Pancreatic Neuroendocrine Tumors.

Authors:  Dong Wook Lee; Michelle Kang Kim; Ho Gak Kim
Journal:  Clin Endosc       Date:  2017-11-30

Review 8.  Endoscopic ultrasound: Current roles and future directions.

Authors:  Scott R Friedberg; Jesse Lachter
Journal:  World J Gastrointest Endosc       Date:  2017-10-16

9.  B-mode and contrast-enhancement characteristics of small nonincidental neuroendocrine pancreatic tumors.

Authors:  Barbara Braden; Christian Jenssen; Mirko D'Onofrio; Michael Hocke; Uwe Will; Kathleen Möller; Andre Ignee; Yi Dong; Xin-Wu Cui; Adrian Sãftoiu; Christoph F Dietrich
Journal:  Endosc Ultrasound       Date:  2017 Jan-Feb       Impact factor: 5.628

Review 10.  Endoscopic ultrasound (EUS) and the management of pancreatic cancer.

Authors:  Muhammad Nadeem Yousaf; Fizah S Chaudhary; Amrat Ehsan; Alejandro L Suarez; Thiruvengadam Muniraj; Priya Jamidar; Harry R Aslanian; James J Farrell
Journal:  BMJ Open Gastroenterol       Date:  2020-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.